Journal of Molecular Oncology confirms synergistic effects of the Aminex Therapeutics drug AMXT 1501 combined with DFMO
A new peer reviewed report in the journal Molecular Oncology confirms the synergistic effects of the Aminex Therapeutics drug AMXT 1501 combined with DFMO in disrupting the polyamine pathway in Neuroblastoma. Neuroblastoma is a type of cancer affecting nerve cells, primarily afflicts children under the age of 5, and is highly dependent on polyamines to grow and multiply. When DFMO disrupts polyamine biosynthesis in neuroblastoma cells, these cells compensate by increasing their uptake of polyamines from the bloodstream. This article describes how AMXT 1501 inhibits this polyamine uptake and diminishes neuroblastoma cell growth.